THERANEXUS EO -25
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more
Market Cap & Net Worth: THERANEXUS EO -25 (3VG)
THERANEXUS EO -25 (F:3VG) has a market capitalization of $42.81 Million (€41.71 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #23941 globally and #2613 in its home market, demonstrating a -7.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying THERANEXUS EO -25's stock price €3.03 by its total outstanding shares 13765403 (13.77 Million).
THERANEXUS EO -25 Market Cap History: 2020 to 2026
THERANEXUS EO -25's market capitalization history from 2020 to 2026. Data shows change from $272.00 Million to $42.81 Million (-27.09% CAGR).
THERANEXUS EO -25 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how THERANEXUS EO -25's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 3VG by Market Capitalization
Companies near THERANEXUS EO -25 in the global market cap rankings as of March 18, 2026.
Key companies related to THERANEXUS EO -25 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
THERANEXUS EO -25 Historical Marketcap From 2020 to 2026
Between 2020 and today, THERANEXUS EO -25's market cap moved from $272.00 Million to $ 42.81 Million, with a yearly change of -27.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €42.81 Million | +51.50% |
| 2025 | €28.26 Million | +270.37% |
| 2024 | €7.63 Million | -48.67% |
| 2023 | €14.86 Million | -36.78% |
| 2022 | €23.51 Million | -64.25% |
| 2021 | €65.77 Million | -75.82% |
| 2020 | €272.00 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of THERANEXUS EO -25 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $42.81 Million USD |
| MoneyControl | $42.81 Million USD |
| MarketWatch | $42.81 Million USD |
| marketcap.company | $42.81 Million USD |
| Reuters | $42.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.